Literature DB >> 8897559

Mechanism underlying early anaemia in children with familial juvenile nephronophthisis.

S Ala-Mello1, S M Kivivuori, K A Rönnholm, O Koskimies, M A Siimes.   

Abstract

Familial juvenile nephronophthisis (NPH) is a hereditary form of chronic tubulointerstitial nephritis with onset in childhood. About one-third of patients develop anaemia before renal insufficiency. We investigated the pathogenetic mechanisms leading to anaemia by comparing 6 patients with NPH and 12 reference patients with other renal diseases. We studied their iron metabolism and measured transferrin receptor-ferritin ratios. There was no evidence for iron deficiency or haemolysis. The serum erythropoietin concentrations of the patients with NPH (12 +/- 2.3 U/I) were low compared with the 12 reference patients (25 +/- 18.9 U/I). In the 2 patients with NPH who were fully investigated, the pharmacokinetics of recombinant human erythropoietin appeared normal. Thus, anaemia in patients with NPH does not result from iron deficiency or correlate with impaired iron status. The mechanism underlying the anaemia of NPH appears to affect the function or regulation of the cells producing erythropoietin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897559     DOI: 10.1007/s004670050164

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  16 in total

Review 1.  Erythropoietin.

Authors:  A J Erslev
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

Review 2.  Structure-function correlations in erythropoietin formation and oxygen sensing in the kidney.

Authors:  M Le Hir; K U Eckardt; B Kaissling; S T Koury; A Kurtz
Journal:  Klin Wochenschr       Date:  1991-09-03

3.  Variations in serum erythropoietin and transferrin receptor during phlebotomy therapy of hereditary hemochromatosis: a case report.

Authors:  K Thorstensen; K Egeberg; I Romslo; J Dalhøj; P Wiggers
Journal:  Eur J Haematol       Date:  1991-09       Impact factor: 2.997

4.  Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial.

Authors:  V S Lim; R L DeGowin; D Zavala; P T Kirchner; R Abels; P Perry; J Fangman
Journal:  Ann Intern Med       Date:  1989-01-15       Impact factor: 25.391

5.  Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia.

Authors:  B J Ferguson; B S Skikne; K M Simpson; R D Baynes; J D Cook
Journal:  J Lab Clin Med       Date:  1992-04

6.  The nephronophthisis complex. A clinicopathologic study in children.

Authors:  R Waldherr; T Lennert; H P Weber; H J Födisch; K Schärer
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

7.  Juvenile nephronophthisis and renal medullary cystic disease.

Authors:  K D Gardner
Journal:  Perspect Nephrol Hypertens       Date:  1976

8.  Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men.

Authors:  K K Flaharty; J Caro; A Erslev; J J Whalen; E M Morris; T D Bjornsson; P H Vlasses
Journal:  Clin Pharmacol Ther       Date:  1990-05       Impact factor: 6.875

9.  Intact transferrin receptors in human plasma and their relation to erythropoiesis.

Authors:  H A Huebers; Y Beguin; P Pootrakul; D Einspahr; C A Finch
Journal:  Blood       Date:  1990-01-01       Impact factor: 22.113

10.  Serum transferrin receptor for assessment of iron status in healthy prepubertal and early pubertal boys.

Authors:  S M Kivivuori; R Anttila; L Viinikka; K Pesonen; M A Siimes
Journal:  Pediatr Res       Date:  1993-09       Impact factor: 3.756

View more
  9 in total

Review 1.  Ciliopathies.

Authors:  Daniela A Braun; Friedhelm Hildebrandt
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-03-01       Impact factor: 10.005

Review 2.  Nephronophthisis and related syndromes.

Authors:  Matthias T F Wolf
Journal:  Curr Opin Pediatr       Date:  2015-04       Impact factor: 2.856

3.  Phenotypic Spectrum of Children with Nephronophthisis and Related Ciliopathies.

Authors:  Jens König; Birgitta Kranz; Sabine König; Karl Peter Schlingmann; Andrea Titieni; Burkhard Tönshoff; Sandra Habbig; Lars Pape; Karsten Häffner; Matthias Hansen; Anja Büscher; Martin Bald; Heiko Billing; Raphael Schild; Ulrike Walden; Tobias Hampel; Hagen Staude; Magdalena Riedl; Norbert Gretz; Martin Lablans; Carsten Bergmann; Friedhelm Hildebrandt; Heymut Omran; Martin Konrad
Journal:  Clin J Am Soc Nephrol       Date:  2017-11-16       Impact factor: 8.237

4.  Endothelial marker-expressing stromal cells are critical for kidney formation.

Authors:  Elina Mukherjee; Katherine Maringer; Emily Papke; Daniel Bushnell; Caitlin Schaefer; Rafael Kramann; Jacqueline Ho; Benjamin D Humphreys; Carlton Bates; Sunder Sims-Lucas
Journal:  Am J Physiol Renal Physiol       Date:  2017-05-24

5.  Association of Nephronophthisis 4 genetic variation with cardiorenal syndrome and cardiovascular events in Japanese general population: the Yamagata (Takahata) study.

Authors:  Yoichiro Otaki; Tetsu Watanabe; Junya Sato; Yuta Kobayashi; Tomonori Aono; Yuji Saito; Jun Goto; Hiroki Takahashi; Takanori Arimoto; Hidenori Sato; Tsuneo Konta; Yoshiyuki Ueno; Masafumi Watanabe
Journal:  Heart Vessels       Date:  2021-09-30       Impact factor: 2.037

Review 6.  Nephronophthisis: disease mechanisms of a ciliopathy.

Authors:  Friedhelm Hildebrandt; Massimo Attanasio; Edgar Otto
Journal:  J Am Soc Nephrol       Date:  2008-12-31       Impact factor: 10.121

Review 7.  Cystic kidney diseases: many ways to form a cyst.

Authors:  Hannah Loftus; Albert C M Ong
Journal:  Pediatr Nephrol       Date:  2012-06-27       Impact factor: 3.714

8.  Nephronophthisis: a genetically diverse ciliopathy.

Authors:  Roslyn J Simms; Ann Marie Hynes; Lorraine Eley; John A Sayer
Journal:  Int J Nephrol       Date:  2011-05-15

Review 9.  Nephronophthisis-Pathobiology and Molecular Pathogenesis of a Rare Kidney Genetic Disease.

Authors:  Shabarni Gupta; Justyna E Ozimek-Kulik; Jacqueline Kathleen Phillips
Journal:  Genes (Basel)       Date:  2021-11-05       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.